Statin Intensity and Coronary Allograft Vasculopathy After Heart Transplantation
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The investigator's propose to conduct an open-label randomized controlled trial to determine
if higher intensity statin (HS) can reduce CAV in comparison to lower intensity statin (LS)
after HT. All consecutive patients that meet eligibility criteria will be approached for
participation. After heart transplantation, participants (n=70) will be randomized in a 1:1
manner to either HS (Atorvastatin 40 mg daily) or LS (Pravastatin 40 mg daily). Study
participation will be for 2 years from the time of randomization.